Revance Therapeutics (RVNC) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
Revance Therapeutic (RVNC) PT Lowered to $42 at Mizuho Securities
November 2, 2018 7:25 AM EDTMizuho Securities analyst, Difei Yang, lowered the price target on Revance Therapeutic (NASDAQ: RVNC) to $42.00 (from $48.00) while maintaining a Buy rating following the company's 3Q earnings report. Revance reported 3Q EPS of $(0.91) that is slightly above FactSet consensus of $(0.92). $2.4 mil of revenue was... More



